Literature DB >> 17273654

Comparison of two questionnaires which measure the health-related quality of life of idiopathic pulmonary fibrosis patients.

C S Zimmermann1, C R F Carvalho, K R Silveira, W P S Yamaguti, E V Moderno, J M Salge, R A Kairalla, C R R Carvalho.   

Abstract

The objective of the present study was to determine if there is a health-related quality of life (HRQL) instrument, generic or specific, that better represents functional capacity dysfunction in idiopathic pulmonary fibrosis (IPF) patients. HRQL was evaluated in 20 IPF patients using generic and specific questionnaires (Medical Outcomes Short Form 36 (SF-36) and Saint George's Respiratory Questionnaire (SGRQ), respectively). Functional status was evaluated by pulmonary function tests, 6-min walking distance test (6MWDT) and dyspnea indexes (baseline dyspnea index) at rest and after exercise (modified Borg scale). There was a restrictive pattern with impairment of diffusion capacity (total lung capacity, TLC = 71.5 +/- 15.6%, forced vital capacity = 70.4 +/- 19.4%, and carbon monoxide diffusing capacity = 41.5 +/- 16.2% of predicted value), a reduction in exercise capacity (6MWDT = 435.6 +/- 95.5 m) and an increase of perceived dyspnea score at rest and during exercise (6 +/- 2.5 and 7.1 +/- 1.3, respectively). Both questionnaires presented correlation with some functional parameters (TLC, forced expiratory volume in 1 s and carbon monoxide diffusing capacity) and the best correlation was with TLC. Almost all of the SGRQ domains presented a strong correlation with functional status, while in SF-36 only physical function and vitality presented a good correlation with functional status. Dyspnea index at rest and 6MWDT also presented a good correlation with HRQL. Our results suggest that a specific instead of a generic questionnaire is a more appropriate instrument for HRQL evaluation in IPF patients and that TLC is the functional parameter showing best correlation with HRQL.

Entities:  

Mesh:

Year:  2007        PMID: 17273654     DOI: 10.1590/s0100-879x2007000200004

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  10 in total

1.  Identifying Mechanisms of Homeostatic Signaling in Fibroblast Differentiation.

Authors:  Hayley C Warsinske; Shanna L Ashley; Jennifer J Linderman; Bethany B Moore; Denise E Kirschner
Journal:  Bull Math Biol       Date:  2015-09-18       Impact factor: 1.758

Review 2.  The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review.

Authors:  Jeffrey J Swigris; Dirk Esser; Craig S Conoscenti; Kevin K Brown
Journal:  Health Qual Life Outcomes       Date:  2014-08-20       Impact factor: 3.186

Review 3.  Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis.

Authors:  Amy L Olson; Kevin K Brown; Jeffrey J Swigris
Journal:  Patient Relat Outcome Meas       Date:  2016-05-17

4.  Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry.

Authors:  Michael Kreuter; Jeff Swigris; David Pittrow; Silke Geier; Jens Klotsche; Antje Prasse; Hubert Wirtz; Dirk Koschel; Stefan Andreas; Martin Claussen; Christian Grohé; Henrike Wilkens; Lars Hagmeyer; Dirk Skowasch; Joachim F Meyer; Joachim Kirschner; Sven Gläser; Felix J F Herth; Tobias Welte; Claus Neurohr; Martin Schwaiblmair; Matthias Held; Thomas Bahmer; Marion Frankenberger; Jürgen Behr
Journal:  Respir Res       Date:  2017-07-14

5.  The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.

Authors:  Alex Diamantopoulos; Emily Wright; Katerina Vlahopoulou; Laura Cornic; Nils Schoof; Toby M Maher
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

6.  Diaphragmatic ultrasound findings correlate with dyspnea, exercise tolerance, health-related quality of life and lung function in patients with fibrotic interstitial lung disease.

Authors:  Pauliane Vieira Santana; Leticia Zumpano Cardenas; André Luis Pereira de Albuquerque; Carlos Roberto Ribeiro de Carvalho; Pedro Caruso
Journal:  BMC Pulm Med       Date:  2019-10-21       Impact factor: 3.317

7.  Study protocol for a randomised, placebo-controlled, single-blind phase II study of the efficacy of morphine for dyspnoea in patients with interstitial lung disease (JORTC-PAL 15).

Authors:  Yoshinobu Matsuda; Tatsuya Morita; Shunsuke Oyamada; Keisuke Ariyoshi; Takuhiro Yamaguchi; Satoru Iwase
Journal:  BMJ Open       Date:  2021-05-18       Impact factor: 2.692

8.  Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response.

Authors:  Suzana Pinheiro Pimenta; Bruno Guedes Baldi; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho
Journal:  J Bras Pneumol       Date:  2013 Jan-Feb       Impact factor: 2.624

9.  Computational Modeling Predicts Simultaneous Targeting of Fibroblasts and Epithelial Cells Is Necessary for Treatment of Pulmonary Fibrosis.

Authors:  Hayley C Warsinske; Amanda K Wheaton; Kevin K Kim; Jennifer J Linderman; Bethany B Moore; Denise E Kirschner
Journal:  Front Pharmacol       Date:  2016-06-23       Impact factor: 5.810

Review 10.  A systematic review of literature to evaluate the burden of physical and psychological symptoms and palliative care in patients diagnosed with idiopathic pulmonary fibrosis.

Authors:  M F van Jaarsveld; L Gwyther
Journal:  Afr J Thorac Crit Care Med       Date:  2019-04-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.